Hepatocellular carcinoma in patients with HIV

被引:19
作者
El Dika, Imane [1 ]
Harding, James J. [1 ,2 ]
Abou-Alfa, Ghassan K. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 300 East 66th St, New York, NY 10065 USA
[2] Weill Cornell Med Coll, New York, NY USA
关键词
hepatocellular carcinoma; highly active antiretroviral therapy; HIV; liver transplantation; screening; sorafenib; HEPATITIS-C VIRUS; INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; NATURAL-HISTORY; LIVER-DISEASE; IMMUNODEFICIENCY; RISK; HEPATOCARCINOMA; EPIDEMIOLOGY; SORAFENIB;
D O I
10.1097/COH.0000000000000335
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review Hepatocellular carcinoma (HCC) is becoming an important cause of mortality in patients with HIV, attributed to coinfection with hepatitis C virus, hepatitis B virus, and the longer survival advantage these patients are achieving after introducing the highly active antiretroviral therapy (HAART) regimens. Recent findings In addition to hepatitis infection, immunosuppression secondary to HIV infection, direct impact of the virus on liver parenchyma, and the use of hepatotoxic antiretroviral drugs, all contribute to HCC pathogenesis. Screening is very important in this particular population; data on population-specific guidelines are still controversial and scarce. Liver transplantation remains the treatment of choice in eligible patients. Trials on sorafenib have not included patients with HIV; yet, we know from small retrospective series that it might be safe and effective. Summary In the HAART era, HCC is arising as a common non-AIDS defining cancer with high impact on morbidity and mortality of HIV-infected patients. Candidates for liver transplantation should be offered this option regardless of HIV infection. Safety and efficacy of sorafenib and other treatment modalities should be further studied and offered as deemed applicable to HIV patients diagnosed with HCC.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 53 条
[1]  
Agijero F, 2016, HEPATOLOGY, V63, P488
[2]   Management of end-stage liver disease in HIV-infected patients [J].
Agueero, Fernando ;
Laguno, Montserrat ;
Moreno, Asuncion ;
Rimola, Antonio ;
Miro, Jose M. .
CURRENT OPINION IN HIV AND AIDS, 2007, 2 (06) :474-481
[3]   Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus-Coinfected Veterans [J].
Anderson, Jeffrey P. ;
Tchetgen, Eric J. Tchetgen ;
Lo Re, Vincent, III ;
Tate, Janet P. ;
Williams, Paige L. ;
Seage, George R., III ;
Horsburgh, C. Robert ;
Lim, Joseph K. ;
Goetz, Matthew Bidwell ;
Rimland, David ;
Rodriguez-Barradas, Maria C. ;
Butt, Adeel A. ;
Klein, Marina B. ;
Justice, Amy C. .
CLINICAL INFECTIOUS DISEASES, 2014, 58 (05) :719-727
[4]  
[Anonymous], 2016, J CLIN ONCOL S
[5]   Human immunodeficiency virus-related microbial translocation and progression of hepatitis C [J].
Balagopal, Ashwin ;
Philp, Frances H. ;
Astemborski, Jacquie ;
Block, Timothy M. ;
Mehta, Anand ;
Long, Ronald ;
Kirk, Gregory D. ;
Mehta, Shruti H. ;
Cox, Andrea L. ;
Thomas, David L. ;
Ray, Stuart C. .
GASTROENTEROLOGY, 2008, 135 (01) :226-233
[6]   Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients [J].
Berretta, Massimiliano ;
Di Benedetto, Fabrizio ;
Dal Maso, Luigino ;
Cacopardo, Bruno ;
Nasti, Guglielmo ;
Facchini, Gaetano ;
Bearz, Alessandra ;
Spina, Michele ;
Garlassi, Elisa ;
De Re, Valli ;
Fiorica, Francesco ;
Lleshi, Arben ;
Tirelli, Umberto .
ANTI-CANCER DRUGS, 2013, 24 (02) :212-218
[7]   Presentation and outcome of hepatocellular carcinoma in HIV-infected patients:: A US-Canadian multicenter study [J].
Braeu, Norbert ;
Fox, Rena K. ;
Xiao, Peiying ;
Marks, Kristen ;
Naqvi, Zeenat ;
Taylor, Lynn E. ;
Trikha, Anita ;
Sherman, Morris ;
Sulkowski, Mark S. ;
Dieterich, Douglas T. ;
Rigsby, Michael O. ;
Wright, Teresa L. ;
Hernandez, Maria D. ;
Jain, Mamta K. ;
Khatri, Gajendra K. ;
Sterling, Richard K. ;
Bonacini, Maurizio ;
Martyn, Catherine A. ;
Aytaman, Ayse ;
Llovet, Josep M. ;
Brown, Sheldon T. ;
Bini, Edmund J. .
JOURNAL OF HEPATOLOGY, 2007, 47 (04) :527-537
[8]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[9]   HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008 [J].
Bruyand, Mathias ;
Dabis, Francois ;
Vandenhende, Marie-Anne ;
Lazaro, Estibaliz ;
Neau, Didier ;
Leleux, Olivier ;
Geffard, Stephane ;
Morlat, Philippe ;
Chene, Genevieve ;
Bonnet, Fabrice .
JOURNAL OF HEPATOLOGY, 2011, 55 (05) :1058-1062
[10]  
Callegari Elisa, 2013, Onco Targets Ther, V6, P1167, DOI 10.2147/OTT.S36161